SCHEMBL3488697

SCHEMBL3488697

Cc1ccc(Oc2ccc([N+](=O)[O-])c(CNC(=O)O)c2)cc1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.44
SMN1; SMN2 Q16637 6/20 0.44
MEN1 O00255 6/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
POLB P06746 1/20 0.43
ALDH1A1 P00352 10/20 0.42
LMNA P02545 4/20 0.42
HPGD P15428 3/20 0.42
HTT P42858 2/20 0.42
KDM4E B2RXH2 2/20 0.41
MAPT P10636 3/20 0.40
PKM P14618 1/20 0.40
CYP1A2 P05177 1/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
TSHR P16473 2/20 0.40
GAA P10253 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3488700 1.00 KMT2A (0.44) KMT2ASMN1; SMN2MEN1NPC1RAB9A
SCHEMBL3487468 0.89 MEN1 (0.42) KMT2ASMN1; SMN2MEN1NPC1RAB9A
SCHEMBL3487476 0.89 MEN1 (0.42) KMT2ASMN1; SMN2MEN1NPC1RAB9A
SCHEMBL3487273 0.89 HTR2A (0.43) KMT2ASMN1; SMN2MEN1NPC1RAB9A
SCHEMBL3487281 0.89 HTR2A (0.43) KMT2ASMN1; SMN2MEN1NPC1RAB9A
SCHEMBL3487592 0.88 ALDH1A1 (0.43) KMT2ASMN1; SMN2MEN1NPC1RAB9A
SCHEMBL3487595 0.88 ALDH1A1 (0.43) KMT2ASMN1; SMN2MEN1NPC1RAB9A
SCHEMBL3488427 0.88 PTPN1 (0.48) KMT2ASMN1; SMN2MEN1NPC1RAB9A
SCHEMBL3488422 0.88 PTPN1 (0.48) KMT2ASMN1; SMN2MEN1NPC1RAB9A
SCHEMBL3487477 0.85 KMT2A (0.42) KMT2ASMN1; SMN2MEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2138484-B1 FUSED BICYCLIC HETEROARYL DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2015-08-26 EP disclosed
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2138484-A1 FUSED BICYCLIC HETEROARYL DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE PPARG, GPR119, PPARA KMT2A 2465/4885SMN1; SMN2 4397/4885MEN1 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.